Lv7
3770 积分 2022-04-01 加入
Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study
17天前
已完结
MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications
17天前
已完结
DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC
18天前
已完结
EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax
2个月前
已关闭
EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax
2个月前
已关闭
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
2个月前
已完结
CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab
2个月前
已关闭
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
3个月前
已完结
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
3个月前
已完结
BCL ‐2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma
3个月前
已完结
皖公网安备34019202002308
